EGFR and lung carcinoma: Recently, several studies examined the presence of EGFR mutations in lung cancer by immunohistochemistry (IHC) using the two mutation-specific antibodies employed in the present study and demonstrated sensitivity ranging from 24% to 100% and specificity ranging from 77% to 100% [16–23].